Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies

Bała, Małgorzata M; Paszek, Elżbieta; Wloch-Kopec, Dorota; Leśniak, Wiktoria; Undas, Anetta

doi:10.1002/14651858.cd012534

Cited by 9 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 Regarding oral anticoagulation, with or without LDA, the quality of evidence is too low to demonstrate benefit or harm of anticoagulant use in aPL carriers. 73 In women with a high-risk aPL profile but no history of thrombosis or pregnancy complications, treatment with LDA (75-100 mg daily) during pregnancy should be considered according to 2019 European League Against Rheumatism (EULAR) recommendations.…”

Section: Antiphospholipid Antibody Carriersmentioning

confidence: 99%

Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management

et al. 2020

View full text Add to dashboard Cite

Section: Antiphospholipid Antibody Carriersmentioning

confidence: 99%

Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management

et al. 2020

View full text Add to dashboard Cite

“…108 A recent Cochrane Database systematic review concluded that there is not enough evidence to demonstrate benefit or damage of several different treatments in patients with positive aPL and recurrent pregnancy loss for primary prevention of thrombotic events. 114…”

Section: Thrombosis After Obstetric Aps (Summary Prepared By Dr Guilmentioning

confidence: 99%

16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

Jesús

Benson

Chighizola

et al. 2020

Lupus

View full text Add to dashboard Cite

Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.

show abstract

“…APS is an autoimmune disorder characterized by venous or arterial thrombosis with laboratory evidence of antiphospholipid antibodies [ 4 ]. In patients with positive phospholipid antibodies with no history of acute thrombosis, primary thrombosis prevention with aspirin or anticoagulant is usually not recommended based on various trials [ 5 - 7 ]. For non-pregnant patients with APS, warfarin is preferred over DOACs.…”

Section: Discussionmentioning

confidence: 99%

When Blood Is Being Difficult: Clotting and Bleeding in a Patient With Antiphospholipid Antibody Syndrome and Supratherapeutic International Normalized Ratio

Tiperneni¹,

Tayyeb²,

Fichadiya³

et al. 2022

Cureus

View full text Add to dashboard Cite

Venous thromboembolism includes deep venous thrombosis (DVT) and pulmonary embolism and is the most common cardiovascular disease after coronary artery disease and stroke. Antiphospholipid syndrome (APS) is an autoimmune disorder that is characterized by venous or arterial thrombosis with laboratory evidence of antiphospholipid antibodies. Long-term anticoagulation therapy is required to prevent recurrent DVTs, embolisms, and thrombosis-related complications. Treatment options include vitamin K antagonists, subcutaneous low-molecular-weight heparin, unfractionated heparin, or direct oral anticoagulants. Warfarin (a vitamin K antagonist) remains the mainstay of treatment in APS patients with a prior history of DVT and is associated with elevation of the international normalized ratio which is often used as a marker for therapy appropriateness and warfarin dosing. Here, we describe a unique case of a 65-year-old female with APS on warfarin (given prior lower extremity DVT) presenting with bleeding/hematoma in the left breast and a clot in the left upper extremity.

show abstract

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies

Cited by 9 publications

References 43 publications

Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management

Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management

16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

When Blood Is Being Difficult: Clotting and Bleeding in a Patient With Antiphospholipid Antibody Syndrome and Supratherapeutic International Normalized Ratio

Contact Info

Product

Resources

About